Tag Archives: SMA

December, 2018

April, 2018

December, 2017

October, 2017

March, 2017

  • 17 March

    AveXis’ Gene Therapy for SMA Demonstrates Positive Results

    CHICAGO, March 16, 2017 (GLOBE NEWSWIRE) — AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today reported topline results from the Phase 1 trial of AVXS-101 in spinal muscular atrophy (SMA) Type 1. The company also reported financial …

January, 2017

December, 2016

July, 2016

  • 22 July

    FDA Grants Breakthrough Therapy Designation to AveXis’ Gene Therapy

    CHICAGO, July 20, 2016 (GLOBE NEWSWIRE) — AveXis, Inc., (Nasdaq:AVXS) a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for AVXS-101, the company’s lead development candidate for the …

May, 2016

  • 4 May

    Biogen to Spin Off Hemophilia Business into Separate Company

    CAMBRIDGE, Mass.–(BUSINESS WIRE)–Biogen Inc. (NASDAQ: BIIB) today announced that it intends to spin off its hemophilia business as an independent, publicly traded company. The strategic goal of this transaction is to create two focused companies dedicated to driving current and future value in their respective therapeutic areas of expertise. “We …